TNFRSF17 and plasma cell myeloma: CAR-iNKT cells targeting disialoganglioside (GD2) [19], B-lymphocyte antigen (CD19) [20], or B-cell maturation antigen (BCMA) [21] have demonstrated potent activity across models of neuroblastoma, B-cell lymphomas, and multiple myeloma, respectively.